InvestorWire NewsRoom

Article

Predictive Oncology Inc. (NASDAQ: POAI) Enters into Definitive Agreements for Direct Offering Totaling Estimated $3 Million
February 10, 2021

Predictive Oncology Inc. (NASDAQ: POAI) Enters into Definitive Agreements for Direct Offering Totaling Estimated $3 Million

  • Definitive agreements with institutional, accredited investors call for issuance and sale of more than 3.5 million shares of common stock
  • POAI currently focused on applying AI to develop personalized medical treatments, novel lab media and improved vaccines
  • One of POAI’s highest priorities is building multi-omic predictive models of tumor drug response and outcome

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements with several investors for the sale of common stock (https://ibn.fm/YcBGM). The agreements with several institutional and accredited investors call for the issuance and sale of 3,650,840 shares of common stock; the stock will be sold at a purchase price of $0.842 per share, resulting in gross proceeds of approximately $3 million for POAI.

The announcement noted that the sale was a registered direct offering priced at-the-market under Nasdaq rules. As part of the agreements, POAI will also issue unregistered warrants to the investors for the purchase of up to 1,825,420 shares of common stock. The offering is expected to close on or about Jan. 12, 2021 and is subject to customary closing conditions. Predictive Oncology plans to use the proceeds from the offering for working capital purposes.

POAI is currently focused on applying AI to develop improved vaccines, personalized medical treatments, and lab media that replicates the body. The company intends to do this by leveraging the invaluable expertise, information and technology available from its subsidiaries Helomics, TumorGenesis and Soluble.

One of POAI’s highest priorities is building multi-omic predictive models of tumor drug response and outcome. The company accomplishes this by using Helomics proprietary TumorSpace knowledge base of 150,000 tumor drug response profiles gathered from more than 15 years of clinical testing. Helomics’ database, the largest of its kind in the world, includes information gathered from ovarian, colon, pancreas, and head and neck tumors. The company’s CLIA-certified lab conducts testing and provides information designed to support oncologists in pinpointing personalized patient-treatment options.

POAI’s wholly owned TumorGenesis subsidiary specializes in the field of ovarian cancer, developing tools (kits, reagents and specialty cell-culture media) to grow tumors and cancer cells in a manner that mimics the patient’s own body.  TumorGenesis’ proprietary Oncology Capture Technology Platform isolates and cultures the patient’s heterogenous tumor sample, providing a much better model of the tumor outside the body (ex vivo). These improved ex-vivo tumor models can then be used by researchers to investigate cancer and by clinicians to develop patient-specific treatment plans.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.  

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).